Noopept

Noopept, also known by its international nonproprietary name omberacetam and development code GVS-111, is a synthetic dipeptide-derived nootropic developed at the Zakusov Institute of Pharmacology in Russia. Its chemical name is N-phenylacetyl-L-prolylglycine ethyl ester, and its structure incorporates modified proline and glycine residues. Although developed as a functional analogue of piracetam, Noopept is chemically distinct from conventional racetam drugs. It is primarily investigated for its effects on memory, learning, neurotrophic signaling, and cellular responses to neurological injury. Its metabolism produces cycloprolylglycine (cPG), a naturally occurring cyclic dipeptide with biological activity in experimental models.

Noopept has been evaluated in small human studies involving cognitive impairment associated with cerebrovascular disease, traumatic brain injury, and ischemic stroke. These investigations reported improvements in selected cognitive and behavioral measurements, while animal and laboratory research demonstrated effects on BDNF, NGF, hippocampal neurotransmission, oxidative stress, and amyloid-related cellular injury. However, the available human studies are predominantly open-label and lack rigorous placebo controls. Noopept is marketed as a medicine in Russia but is not FDA-approved, and its effectiveness for enhancing cognition in otherwise healthy people, preventing dementia, or treating neurodegenerative diseases has not been established.

Noopept has been investigated for several neurological mechanisms involving peptide metabolism, neurotrophic signaling, hippocampal neurotransmission, and cellular stress responses. Much of the mechanistic evidence comes from rodent and cell-culture studies rather than direct demonstrations in humans.

1. Formation of Cycloprolylglycine (cPG)

• Noopept is a modified derivative of the amino acids proline and glycine.
• After administration, it undergoes metabolism that can generate cycloprolylglycine (cPG), a naturally occurring cyclic dipeptide.
• cPG has demonstrated memory-related and anxiolytic activity in selected animal studies.
• Researchers propose that cPG contributes to Noopept's longer-lasting biological effects after the parent compound has been metabolized.
• However, not every biological action of Noopept has been conclusively attributed to cPG.

2. Rapid Absorption and Brain Exposure

• Noopept was designed to be active following oral administration.
• Animal experiments demonstrated relatively rapid absorption and entry into brain tissue.
• Rodent studies reported a short elimination half-life of approximately 5–10 minutes for the parent compound.
• The circulating metabolite cPG has different pharmacokinetic properties and persists longer in experimental models.
• The Russian product information reports different pharmacokinetic estimates for human use, so rodent half-life values should not be treated as universal human measurements.

3. BDNF and NGF Signaling

• Brain-derived neurotrophic factor (BDNF) supports neuronal survival, synaptic plasticity, and learning-related processes.
• Nerve growth factor (NGF) participates in the maintenance of selected neuronal populations.
• A 2008 rat study found that Noopept increased hippocampal expression of BDNF and NGF messenger RNA.
• After acute administration, expression of these neurotrophins decreased in the cerebral cortex while increasing in the hippocampus.
• Repeated administration over 28 days did not produce tolerance to the observed hippocampal neurotrophin response in that animal model.
• These findings do not establish increased BDNF or NGF in humans taking Noopept.

4. Hippocampal Cholinergic and GABAergic Signaling

• The hippocampus plays an important role in memory formation and learning.
• Acetylcholine and GABA participate in regulating hippocampal neuronal activity.
• A 2022 study using rat hippocampal slices demonstrated that Noopept increased the activity of certain inhibitory interneurons.
• This effect increased inhibitory postsynaptic signaling in CA1 pyramidal neurons.
• Blocking alpha-7 nicotinic acetylcholine receptors prevented the experimental response.
• These findings indicate involvement of alpha-7 nicotinic receptor-related pathways, but do not establish Noopept as a direct receptor agonist in humans.

5. HIF-1 and Cellular Stress Signaling

• Hypoxia-inducible factor-1 (HIF-1) is a transcriptional regulator involved in cellular adaptation to low oxygen availability.
• In a 2016 cell-based experiment, Noopept increased HIF-1-related reporter activity at a concentration of 10 micromolar.
• Other transcription factor pathways evaluated in that experiment did not show the same response.
• Molecular docking suggested possible interactions with prolyl hydroxylase-2, an enzyme involved in regulating HIF-1 alpha stability.
• Docking predictions and reporter assays do not independently demonstrate direct enzyme inhibition or clinical protection against hypoxia.

6. Amyloid-Beta and Tau-Related Research

• Amyloid-beta and abnormal tau signaling are involved in the biology of Alzheimer's disease.
• A 2014 laboratory study examined Noopept in PC12 cells exposed to an amyloid-beta fragment.
• Experimental pretreatment reduced reactive oxygen species, intracellular calcium overload, and apoptosis-related measurements.
• Researchers also observed reduced tau phosphorylation at serine-396 and improved selected mitochondrial measurements.
• These findings provide a rationale for further research but do not establish treatment or prevention of Alzheimer's disease.

7. Alpha-Synuclein Aggregation

• Alpha-synuclein is a protein involved in Parkinson's disease-related neurobiology.
• A 2011 study investigated Noopept's interactions with toxic alpha-synuclein oligomers.
• Researchers observed that Noopept influenced aggregation and promoted formation of larger fibrillar structures under laboratory conditions.
• This was associated with reduced toxicity in cultured neuroblastoma cells.
• No clinical evidence establishes that Noopept treats or prevents Parkinson's disease.

8. Antioxidant and Mitochondrial Research

• Experimental neurological injury can involve oxidative stress, calcium dysregulation, and mitochondrial dysfunction.
• Cell studies demonstrated that Noopept improved selected markers of mitochondrial function during amyloid-related injury.
• Animal studies have also investigated oxidative and metabolic responses following cerebral ischemia.
• These effects remain preclinical and should not be interpreted as proven systemic antioxidant or mitochondrial benefits in humans.

The Key Difference: Noopept is an orally active dipeptide-derived compound with several proposed neurological mechanisms. Its preclinical effects are broader than its established human clinical evidence, and no single molecular pathway has been shown to fully explain its clinical activity.

Researchers are interested in Noopept because it combines oral activity with preliminary human clinical evidence and a substantial body of preclinical neurological research.

• Cognitive Impairment: Small human studies reported improvements in selected cognitive measurements in patients with vascular or post-traumatic brain conditions.
• Memory and Learning: Rodent experiments demonstrated improvements in selected learning and memory tasks.
• BDNF and NGF: Animal studies found changes in hippocampal neurotrophin expression.
• Neuroplasticity: Research suggests involvement in pathways related to neuronal adaptation and maintenance.
• Stroke Recovery: An open-label clinical study evaluated cognitive outcomes in patients following ischemic stroke.
• Alzheimer's Research: Laboratory experiments demonstrated protection against selected amyloid-beta-related cellular effects.
• Parkinson's Research: Noopept influenced alpha-synuclein aggregation in an experimental cell model.
• Hippocampal Signaling: Experiments identified modulation of inhibitory neurotransmission involving alpha-7 nicotinic acetylcholine receptor-related pathways.
• Hypoxia Research: Cell-based studies investigated HIF-1-related signaling.
• Oral Peptide Drug Development: Noopept provides an example of using chemical modification to develop a biologically active dipeptide-derived compound.

Research Limitation: Most human studies involved patients with neurological impairment rather than healthy adults. Their generally small, open-label designs limit confidence in treatment effectiveness and do not establish routine cognitive enhancement.

Noopept has demonstrated preliminary activity in human cognitive-impairment studies and more extensive effects in laboratory and animal research. The strength of evidence varies substantially by application, and findings from neurological disease populations should not be generalized to healthy individuals.

Published Human and Preclinical Findings

Notable 2008 Human Study: Neznamov and Teleshova compared Noopept at 20 mg daily with piracetam at 1,200 mg daily in patients experiencing mild-to-moderate cognitive impairment associated with cerebrovascular disease or traumatic brain injury. Both groups showed improvements in selected outcomes over 56 days.

MMSE Finding: In the Noopept treatment group, the average Mini-Mental State Examination score reportedly increased from approximately 26 to 29. Because the study was open-label and lacked a placebo arm, the result cannot be attributed entirely to the drug.

Post-Stroke Finding: A 2011 open prospective study evaluated 60 patients following ischemic stroke. Investigators reported improvements in selected cognitive measures after approximately two months of treatment at 20 mg daily. Although the research involved longer observation, this should not be interpreted as proof that every participant continuously received Noopept for twelve months.

BDNF and NGF Finding: A 2008 rat study reported increased hippocampal expression of neurotrophic factors following acute and repeated Noopept administration. Results differed by brain region, with acute cortical expression falling below control levels.

Alzheimer's-Related Cell Finding: In a 2014 study, Noopept pretreatment reduced selected effects of amyloid-beta exposure in PC12 cells, including oxidative stress, apoptosis, mitochondrial dysfunction, and tau phosphorylation.

Parkinson's-Related Laboratory Finding: A 2011 study found that Noopept changed the aggregation behavior of alpha-synuclein and reduced oligomer-associated toxicity in cultured cells.

Hippocampal Neurotransmission: A 2022 study demonstrated changes in inhibitory interneuron activity in rat hippocampal slices. The effects depended on alpha-7 nicotinic receptor-related signaling.

Healthy Adult Cognition: No adequately powered, randomized, double-blind, placebo-controlled human trial has established improved memory, focus, intelligence, learning, or productivity in healthy adults using Noopept.

Neurodegenerative Disease Limitation: Noopept has not been demonstrated to prevent Alzheimer's disease, treat Parkinson's disease, or reliably improve long-term outcomes after stroke.

Research Perspective: Noopept possesses a genuine, though limited, human research history and several biologically interesting preclinical mechanisms. The evidence supports further clinical investigation rather than definitive claims of cognitive enhancement or neuroprotection.

Noopept has been studied primarily through oral administration. Unlike many experimental peptides, it is marketed as a tablet medication in Russia, where its product information provides an established local dosing schedule. However, these instructions do not constitute FDA approval or establish effectiveness for cognitive enhancement in healthy adults.

Published Clinical Dosing and Community-Reported Amounts

Administration Considerations

• Oral Administration: The principal route evaluated in published human studies and used in the registered Russian tablet formulation.
• Russian Formulation: Noopept is marketed in Russia as a 10 mg omberacetam tablet.
• Timing: Russian product instructions divide administration between morning and daytime and advise against administration after 6 PM.
• Food: The Russian product information describes oral administration after meals.
• Sublingual Administration: Commonly discussed informally, but greater bioavailability, faster onset, and improved cognitive effects have not been demonstrated in controlled comparisons.
• Intranasal Administration: Not supported by an established human clinical formulation or dosing program.
• Subcutaneous / Intramuscular Administration: No validated therapeutic dose or established human safety data exist for these routes.
• Reconstitution: Noopept does not require bacteriostatic water or injection preparation for its established oral administration route.
• Half-Life: Rodent studies report rapid parent-compound elimination, but human product information reports different pharmacokinetic values. The elimination of the active metabolite differs from that of the parent drug.
• Storage: Finished Russian tablets are labeled for storage at temperatures not exceeding 25 degrees Celsius. Research-grade powder stability should follow product-specific analytical and storage information.

Important Potency Distinction: Noopept is sometimes promoted as 1,000 times more potent than piracetam. This marketing comparison is based primarily on differences in quantities used rather than a controlled demonstration of 1,000-fold greater cognitive improvement.

Important Animal-to-Human Distinction: Doses expressed in mg/kg for experimental rats should not be directly converted into human treatment regimens. Species differences in pharmacokinetics and neurological responses are substantial.

Research Perspective: Oral Noopept has published human clinical dosing information and an established Russian medicine label. However, the reported community practices are not evidence that it improves healthy-adult cognition, and no FDA-approved therapeutic dosing regimen exists in the United States.

Noopept differs from many experimental peptides because it has been evaluated through defined oral treatment courses in human neurological research. However, no validated dosing cycle exists for enhancing cognition in healthy adults, and long-term prevention of cognitive decline has not been demonstrated.

• 2008 Human Comparative Study: Evaluated oral Noopept over 56 consecutive days.
• 2011 Post-Stroke Study: Reported approximately two months of treatment with longer-term clinical observation.
• Russian Product Instructions: Describe treatment courses of approximately 1.5–3 months.
• Repeat Treatment: Russian labeling permits consideration of another course after approximately one month, according to local medical guidance.
• Animal Neurotrophin Research: Included single-dose experiments and 28-day repeated administration.
• Community Short Cycles: Two to four weeks of use are sometimes described.
• Community Longer Cycles: Four to eight weeks of administration are frequently discussed.
• Community Washout Periods: One to two weeks between courses are commonly suggested without controlled validation.
• Long-Term Exposure: Comprehensive safety information from large, independent, multiyear human studies is lacking.

Tolerance Research: A 2008 rat study found that 28 days of Noopept administration did not reduce the measured hippocampal BDNF and NGF response. However, this result does not establish the absence of clinical tolerance, dependence, or withdrawal effects in humans.

Research Perspective: Existing treatment-course schedules originate from clinical use in neurological patients. No evidence establishes that cycling enhances memory, prevents receptor adaptation, or improves safety for healthy individuals.

Noopept is frequently discussed alongside choline-related supplements, other experimental neuropeptides, and compounds associated with memory or attention. However, there is little controlled human evidence demonstrating additional benefits from these combinations.

Choline Stacking Hypothesis: Community sources sometimes suggest that Noopept increases acetylcholine demand and that supplemental choline prevents headaches. However, no controlled clinical study has established that Noopept depletes choline or that choline supplementation prevents its adverse effects.

Research Perspective: Combining multiple centrally active substances may produce unpredictable effects on attention, anxiety, sleep, and blood pressure. Mechanistic compatibility does not establish improved cognitive performance or long-term safety.

Noopept has a limited published human safety database. Its early clinical studies generally described acceptable tolerability, but adverse effects involving blood pressure, sleep, and irritability were documented. Most human findings come from patients with neurological impairment rather than healthy adults.

Reported Adverse Effects and Safety Concerns

Notable Human Safety Finding: In a comparative study involving 31 Noopept recipients, elevated blood pressure was reported in seven patients, sleep disturbances in five, and irritability in three. These values describe a small group of patients with cognitive impairment and should not be interpreted as precise adverse-event rates for the general population.

Blood Pressure Consideration: The Russian product information specifically identifies possible blood-pressure elevation in patients with hypertension, particularly severe hypertension.

Sleep Consideration: Insomnia and sleep disruption may be relevant for a compound that influences neurological arousal. The established Russian oral formulation is not labeled for late-evening administration.

Important Clinical Distinction: Small human studies and relatively favorable short-term tolerability do not establish long-term safety in healthy adults, especially at doses or through routes not evaluated clinically.

Product Quality: Research-market powders and nonapproved supplements may differ from the regulated pharmaceutical product used in Russian clinical practice. Product purity and label accuracy cannot be assumed.

Research Perspective: Blood-pressure elevation, insomnia, and irritability are documented safety signals that deserve particular attention. Human evidence remains insufficient to establish comprehensive long-term safety or reliably predict drug interactions.

Noopept is registered as a medication in Russia but is not FDA-approved in the United States. Its Russian product information identifies specific contraindications, while additional precautions arise from the limited size and design of its published clinical studies.

• Pregnancy and Breastfeeding: Noopept is contraindicated during pregnancy and lactation under its Russian product instructions.
• Children and Adolescents: The registered Russian product is intended for adults aged 18 years and older.
• Severe Liver Disease: Severe hepatic impairment is listed as a contraindication in Russian labeling.
• Severe Kidney Disease: Severe renal impairment is also listed as a contraindication.
• Known Hypersensitivity: Avoidance is indicated in individuals with known allergy to omberacetam or product ingredients.
• Hypertension: Blood-pressure elevation was reported in clinical research and is specifically addressed in Russian product warnings.
• Cardiovascular Disease: Systematic cardiovascular safety studies remain limited.
• Insomnia: Noopept may worsen sleep disturbances in susceptible individuals.
• Anxiety Disorders: Although some studies reported improvements in emotional symptoms, irritability and restlessness were also documented.
• Bipolar Disorder / Psychosis: Effects on mood activation and psychiatric stability remain insufficiently studied.
• Seizure Disorders: The clinical effects on seizure threshold and anticonvulsant therapy are not adequately established.
• ADHD: Noopept has not been demonstrated to treat ADHD in adequately controlled clinical trials.
• Dementia: Laboratory neuroprotection findings do not establish effectiveness for Alzheimer's disease or other dementias.
• Previous Stroke or Brain Injury: These populations appeared in early research, but treatment decisions require appropriate neurological supervision.
• Prescription Stimulants: Controlled interaction studies are inadequate, particularly regarding blood pressure, arousal, and sleep.
• Antidepressants / Psychiatric Medications: Potential interactions are not adequately characterized.
• Blood Pressure Medications: Interactions and cardiovascular responses should not be assumed predictable.
• Unregulated Research Products: Nonpharmaceutical preparations may contain inaccurate concentrations or other ingredients.

Regulatory Status — Russia: Noopept (omberacetam) is registered as a 10 mg oral tablet medicine for specified cognitive and related symptoms. Its current Russian product information identifies over-the-counter availability.

Regulatory Status — United States: Noopept is not FDA-approved as a drug and does not qualify as a lawful dietary ingredient. The FDA has issued warning letters involving products marketed with Noopept-related therapeutic claims.

Regulatory Status — Australia: Noopept is treated as a prescription-only ingredient under the Australian therapeutic goods framework.

Drug Interaction Distinction: Russian product information states that certain interactions have not been established. This should not be interpreted as proof that Noopept has no clinically meaningful interactions with alcohol, hypnotics, antihypertensives, or stimulants.

Medical Consideration: New cognitive impairment, progressive memory loss, substantial blood-pressure elevation, new neurological symptoms, or significant changes in mood require appropriate medical evaluation rather than reliance on an experimental nootropic.

Published Noopept research has evaluated cognitive testing, neurological function, EEG patterns, neurotrophic signaling, and selected safety measurements. No validated biomarker panel exists for establishing cognitive enhancement or long-term neurological protection from Noopept in healthy adults.

Clinical Trial Measurement: The MMSE was used in historical human research, with reported improvements in the Noopept group over the study period. However, interpretation requires consideration of practice effects, placebo effects, and the absence of blinded controls.

Neurotrophin Consideration: Peripheral blood BDNF measurements do not directly demonstrate hippocampal BDNF expression or improved synaptic plasticity.

Neuroimaging and EEG: Changes in electrical activity or neurological biomarkers should not automatically be interpreted as improved cognitive functioning.

Cardiovascular Safety: Blood pressure deserves attention in research because elevated readings were reported in the human comparative study.

Important Limitation: No laboratory biomarker, cognitive scale, or monitoring interval has been validated specifically to establish Noopept's effectiveness for cognitive enhancement in healthy adults or long-term prevention of neurodegenerative disease.